Wilky BA, et al. - In this study including participants from the US and internationally, researchers evaluated the activity of axitinib (a VEGF receptor tyrosine-kinase inhibitor) plus pembrolizumab (anti-PD-1 immune checkpoint inhibitor) in patients with sarcoma, including alveolar soft-part sarcoma (ASPS). Overall 33 patients were observed over a median duration of 14.7 months. For all evaluable patients and for patients with ASPS, the observed 3-month progression-free survival was 65.6% and 72.7%, respectively. Hypertension (five [15%] of 33 patients), autoimmune toxicities (five [15%]), nausea or vomiting (two [6%]), and seizures (two [6%]) were documented as the most common grade 3 or 4 treatment-related adverse events experienced. Overall, toxicity associated with axitinib plus pembrolizumab was manageable and preliminary activity was evident in patients with advanced sarcomas, especially in patients with ASPS.